Compare AbbVie Inc (ABBV) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.44 with no daily change, reflecting its stable, cash-equivalent nature. Technical indicators signal a bearish trend from moving averages but neutral oscillators, while support and resistance cluster tightly at $100. The ETF offers a low 0.09% expense ratio and yields around 3.54–3.65%, attracting investors seeking short-term Treasury exposure amid rate uncertainty, as highlighted in recent financial news comparing it to peers like BIL.

The outlook for SGOV remains favorable for risk-averse investors prioritizing capital preservation and modest yield, with inflows into bond ETFs surging 60% year-over-year per CNBC (2026-06-25). Key risks include potential Fed rate hikes that could pressure short-term yields and inflation concerns, though its ultra-short duration minimizes interest rate sensitivity compared to longer bonds.